11 recruiting, 3 active not recruiting, 3 terminated, 2 completed. 20 Phase 1, 5 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Recruiting 10, Active not recruiting 3, Terminated 3, Completed 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Recruiting 4, Active not recruiting 1 |
| Not applicable | 2 | Recruiting 1, Unknown 1 |
Follow Solid Tumors, Adult: new trials by email Literature Review of Solid Tumors, Adult trials Research Report on Solid Tumors, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor HMPL-A580 - Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Hutchmed | 186 | 2026-03-04 | 2026-09-18 |
| A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg - Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Abbisko Therapeutics Co, Ltd | 401 | 2026-03-02 | 2026-03-11 |
| A Study of GC203 TIL in Advanced Solid Tumors (NF) GC203 TIL - Solid Tumors, Adult | Phase 1 | Recruiting | Shanghai Juncell Therapeutics | 8 | 2026-01-30 | 2026-08-05 |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors HMPL-A251 - Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Hutchmed | 147 | 2025-12-16 | 2026-09-22 |
| Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy PET/CT Imaging with GZMB-targeted tracer - PET/CT, Solid Tumors, Adult | Not yet recruiting | Zhongnan Hospital | 200 | 2025-04-01 | 2025-04-08 | |
| Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors DCR-PDL1 - Solid Tumors, Adult | Phase 1 | Recruiting | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 32 | 2024-05-29 | 2025-11-06 |
| PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors PANK-003 cell injection - Solid Tumors, Adult | Phase 1 | Recruiting | Shenzhen Celconta Life Science Co., Ltd. | 18 | 2024-02-18 | 2025-03-26 |
| HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose - Solid Tumors, Adult | Phase 1 | Recruiting | HighField Biopharmaceuticals Corporation | 84 | 2023-12-12 | 2026-06-26 |
| Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours Blood glucose stress combined with low-dose chemotherapy - Solid Tumors, Adult | Not applicable | Recruiting | Wuxi People's Hospital | 300 | 2023-09-04 | 2024-05-08 |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors TNG260, Pembrolizumab - Non Small Cell Lung Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Active not recruiting | Tango Therapeutics, Inc. | 126 | 2023-06-12 | 2026-07-06 |
| A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors tumor treatment vaccine injection - Solid Tumors, Adult | Not applicable | Unknown | Wuxi People's Hospital | 50 | 2023-06-07 | 2023-06-13 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
| Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors VP301 - Solid Tumors, Adult, Multiple Myeloma | Phase 1 | Terminated | Virtuoso BINco, Inc. | 2 | 2022-11-29 | 2023-09-21 |
| Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Alpelisib, Carboplatin, Hyperpolarized Carbon-13 (13C) Pyruvate - Solid Tumors, Adult, PIK3CA Mutation-Related Tumors | Phase 1 | Withdrawn | Pamela Munster | 2022-11-01 | 2022-12-27 | |
| GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors GT101 - Solid Tumors, Adult | Phase 1 | Recruiting | Grit Biotechnology | 31 | 2022-05-23 | 2026-09-14 |
| NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors NECVAX-NEO1 - Solid Tumors, Adult | Phase 1 | Active not recruiting | NEC OncoImmunity AS | 6 | 2022-05-05 | 2025-06-26 |
| Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors IK-930, Osimertinib - Solid Tumors, Adult, Solid Tumor | Phase 1 | Terminated | Ikena Oncology | 67 | 2022-01-07 | 2024-11-18 |
| Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors VB10.NEO - Solid Tumors, Adult | Phase 1 | Completed | Nykode Therapeutics ASA | 26 | 2021-12-21 | 2024-12-03 |
| Study of ON 123300 in Patients With Advanced Cancer ON123300 - Solid Tumors, Adult | Phase 1 | Unknown | Traws Pharma, Inc. | 36 | 2021-05-13 | 2023-12-07 |
| TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors TIL injection - Solid Tumors, Adult | Phase 1 | Active not recruiting | Grit Biotechnology | 12 | 2021-04-21 | 2026-09-18 |
Showing 20 of 23. Sign in to see all of them.
Neoplasm Metastasis (3) · Adenocarcinoma of Lung (1) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hemangioendothelioma, Epithelioid (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lipodystrophy, Congenital Generalized (1) · Lung Neoplasms (1) · Lymphoma (1) · Mesothelioma, Malignant (1) · Multiple Myeloma (1) · Neoplasms (1)
Neoplasms (6) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Carcinoma (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Lung Diseases (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Alpelisib (1) · Anastrozole (1) · Carboplatin (1) · Drug Therapy (1) · Drugs, Investigational (1) · Fulvestrant (1) · Imlunestrant (1) · Letrozole (1) · Magnetic Resonance Spectroscopy (1) · Metformin (1) · ON123300 (1) · Pyruvic Acid (1) · STX-478 (1) · Tamoxifen (1) · Toll-Like Receptor 1 (1)
Grit Biotechnology (2) · Hutchmed (2) · Wuxi People's Hospital (2) · Abbisko Therapeutics Co, Ltd (1) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · Eli Lilly and Company (1) · HighField Biopharmaceuticals Corporation (1) · Ikena Oncology (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · NEC OncoImmunity AS (1) · Nykode Therapeutics ASA (1) · Pamela Munster (1) · Shanghai East Hospital (1) · Shanghai Juncell Therapeutics (1) · Shenzhen Celconta Life Science Co., Ltd. (1)
United States (12) · China (11) · Germany (2) · Spain (2) · Australia (1) · Belgium (1) · France (1) · Ireland (1) · Italy (1) · Japan (1) · Lithuania (1) · Netherlands (1) · United Kingdom (1)
Adam Crystal, MD, PhD (1) · Caroline Germa, MD (1) · Elona Juozaityte, MD (1) · Jin Li, MD, PhD (1) · Katherine Kim, MD (1) · Michael E Saunders, MD (1) · Pamela Munster, MD (1) · Siri Torhaug, MD (1) · Thomas Hope, MD (1) · Xianjun Yu, Doctor (1) · Yong He, MD, PhD (1)
2023 (1)